文献速递肝病

增强肝纤维化试验与FibroTest、弹性成像及间接标志物检测酒精性肝病晚期纤维化的准确性比较

Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
PubMed 文献 · Gastroenterology · 2018-01-06

ELF的AUROC为0.92(95%CI 0.89-0.96),与FibroTest(0.90)无显著差异(P=0.209);初级保健患者中ELF<10.5和FibroTest<0.58的阴性预测值分别为98%和94%。

要点

  • ELF检测晚期肝纤维化的AUROC为0.92(95%CI 0.89-0.96),初级与二级保健患者间无显著差异(P=0.917)。
  • ELF与FibroTest诊断准确性相当(FibroTest AUROC 0.90,P=0.209),优于间接标志物检测。
  • 初级保健患者中ELF<10.5和FibroTest<0.58的阴性预测值分别为98%和94%,可排除晚期纤维化。

核心结论

  • 在活检为参考标准的前瞻性直接比较中,ELF和FibroTest对初级和二级保健酒精性肝病患者晚期肝纤维化具有高诊断准确性(AUROC≥0.90)。
  • 初级保健患者中,ELF值低于10.5或FibroTest值低于0.58可排除晚期肝纤维化。

研究设计与样本

  • 前瞻性研究,纳入丹麦南部地区2013年至2016年初级中心(市政酒精康复中心,n=128,6%有晚期纤维化)和二级保健中心(医院门诊,n=161,36%有晚期纤维化)的患者。
  • 在同一天进行10种肝纤维化标志物检测(专利和非专利),以活检证实的纤维化分期为参考标准。
  • 主要目的是验证ELF在初级和二级保健中心酒精性肝病患者中检测晚期纤维化的准确性,使用文献截断值10.5。

主要发现

  • ELF检测晚期肝纤维化的AUROC为0.92(95%CI 0.89-0.96),初级与二级保健患者间无显著差异(P=0.917)。
  • ELF比间接标志物检测更准确地识别晚期肝纤维化患者,但与FibroTest诊断准确性相当(FibroTest AUROC 0.90,与ELF比较P=0.209)。
  • 在意向诊断分析中,ELF和FibroTest与瞬时弹性成像无显著差异(瞬时弹性成像AUROC 0.90,与ELF比较P=0.521),但在符合方案分析中有差异(瞬时弹性成像AUROC 0.97,与ELF比较P=0.004)。
  • 在瞬时弹性成像分析中加入血清标志物并未提高准确性。
  • 初级保健患者中,ELF值低于10.5和FibroTest值低于0.58对晚期肝纤维化的阴性预测值分别为98%和94%。

关键数值与推荐

  • ELF检测晚期肝纤维化(Kleiner分期≥F3)的AUROC为0.92(95%CI 0.89-0.96)。
  • FibroTest检测晚期肝纤维化的AUROC为0.90。
  • 瞬时弹性成像检测晚期肝纤维化的AUROC在意向诊断分析中为0.90,在符合方案分析中为0.97。
  • 初级保健患者中ELF<10.5对晚期肝纤维化的阴性预测值为98%,FibroTest<0.58的阴性预测值为94%。

临床怎么用

  • 在初级保健酒精性肝病患者中,ELF值低于10.5或FibroTest值低于0.58可排除晚期肝纤维化。
  • ELF和FibroTest对晚期肝纤维化具有高诊断准确性,可用于初级和二级保健患者的无创评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Alcohol is the leading cause of cirrhosis and liver-related mortality, but we lack serum markers to detect compensated disease. We compared the accuracy of the Enhanced Liver Fibrosis test (ELF), the FibroTest, liver stiffness measurements (made by transient elastography and 2-dimensional shear-wave elastography), and 6 indirect marker tests in detection of advanced liver fibrosis (Kleiner stage ≥F3). METHODS: We performed a prospective study of 10 liver fibrosis markers (patented and not), all performed on the same day. Patients were recruited from primary centers (municipal alcohol rehabilitation, n = 128; 6% with advanced fibrosis) and secondary health care centers (hospital outpatient clinics, n = 161; 36% with advanced fibrosis) in the Region of Southern Denmark from 2013 through 2016. Biopsy-verified fibrosis stage was used as the reference standard. The primary aim was to validate ELF in detection of advanced fibrosis in patients with alcoholic liver disease recruited from primary and secondary health care centers, using the literature-based cutoff value of 10.5. Secondary aims were to assess the diagnostic accuracy of ELF for significant fibrosis and cirrhosis and to determine whether combinations of fibrosis markers increase diagnostic yield. RESULTS: The ELF identified patients with advanced liver fibrosis with an area under the receiver operating characteristic curve (AUROC) of 0.92 (95% confidence interval 0.89-0.96); findings did not differ significantly between patients from primary vs secondary care (P = .917). ELF more accurately identified patients with advanced liver fibrosis than indirect marker tests, but ELF and FibroTest had comparable diagnostic accuracies (AUROC of FibroTest, 0.90) (P = .209 for comparison with ELF). Results from the ELF and FibroTest did not differ significantly from those of liver stiffness measurement in intention-to-diagnose analyses (AUROC for transient elastography, 0.90), but did differ in the per-protocol analysis (AUROC for transient elastography, 0.97) (P = .521 and .004 for comparison with ELF). Adding a serum marker to transient elastography analysis did not increase accuracy. For patients in primary care, ELF values below 10.5 and FibroTest values below 0.58 had negative predictive values for advanced liver fibrosis of 98% and 94%, respectively. CONCLUSION: In a prospective, direct comparison of tests, ELF and FibroTest identified advanced liver fibrosis in alcoholic patients from primary and secondary care with high diagnostic accuracy (AUROC values of 0.90 or higher using biopsy as reference). Advanced fibrosis can be ruled out in primary health care patients based on an ELF value below 10.5 or a FibroTest value below 0.58.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Thiele M, Madsen BS, Hansen JF, et al. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology. 2018. PMID: 29317276. doi:10.1053/j.gastro.2018.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。